Journal of Surgery Concepts & Practice >
Radiotherapy in management of pancreatic cancer: application and prospect
WU Lili, XU Yaolin, LOU Wenhui . Radiotherapy in management of pancreatic cancer: application and prospect[J]. Journal of Surgery Concepts & Practice, 2022 , 27(01) : 25 -29 . DOI: 10.16139/j.1007-9610.2022.01.007
| [1] | Cai J, Chen H, Lu M, et al. Advances in the epidemiology of pancreatic cancer: Trends, risk factors, screening, and prognosis[J]. Cancer Letters, 2021, 520:1-11. |
| [2] | Kalser MH, Ellenberg SS. Pancreatic cancer. adjuvant combined radiation and chemotherapy following curative resection[J]. Arch Surg, 1985, 120(8):899-903. |
| [3] | Gastrointestinal Tumor Study Group. Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer[J]. Cancer, 1987, 59(12):2006-2010. |
| [4] | Smeenk HG, van Eijck CH, Hop WC, et al. Long-term survival and metastatic pattern of pancreatic and periampullary cancer after adjuvant chemoradiation or observation: long-term results of EORTC trial 40891[J]. Ann Surg, 2007, 246(5):734-740. |
| [5] | Klinkenbijl JH, Jeekel J, Sahmoud T, et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase Ⅲ trial of the EORTC gastrointestinal tract cancer co-operative group[J]. Ann Surg, 1999, 230(6):776-782. |
| [6] | Regine WF, Winter KA, Abrams R, et al. Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the U.S. Intergroup/RTOG 9704 phase Ⅲ trial[J]. Ann Surg Oncol, 2011, 18(5):1319-1326. |
| [7] | Regine WF, Winter KA, Abrams RA, et al. Fluorouracil vs. gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial[J]. JAMA, 2008, 299(9):1019-1026. |
| [8] | Rutter CE, Park HS, Corso CD, et al. Addition of radiotherapy to adjuvant chemotherapy is associated with improved overall survival in resected pancreatic adenocarcinoma: an analysis of the national cancer data base[J]. Cancer, 2015, 121(23):4141-4149. |
| [9] | Hsu CC, Herman JM, Corsini MM, et al. Adjuvant chemoradiation for pancreatic adenocarcinoma: the Johns Hopkins Hospital-Mayo Clinic collaborative study[J]. Ann Surg Oncol, 2010, 17(4):981-990. |
| [10] | Neoptolemos JP, Stocken DD, Friess H, et al. A rando-mized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer[J]. N Engl J Med, 2004, 350(12):1200-1210. |
| [11] | Neoptolemos JP, Dunn JA, Stocken DD, et al. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial[J]. Lancet, 2001, 358(9293):1576-1585. |
| [12] | van Laethem JL, Hammel P, Mornex F, et al. Adjuvant gemcitabine alone versus gemcitabine-based chemoradiotherapy after curative resection for pancreatic cancer: a randomized EORTC-40013-22012/FFCD-9203/GERCOR phase Ⅱ study[J]. J Clin Oncol, 2010, 28(29):4450-4456. |
| [13] | Naffouje SA, Sabesan A, Kim DW, et al. Adjuvant chemoradiotherapy in resected pancreatic ductal adenocarcinoma: where does the benefit lie? a nomogram for risk stratification and patient selection[J]. J Gastrointest Surg, 2021-09-10[online ahead of print]. |
| [14] | Abrams RA, Winter KA, Regine WF, et al. Failure to adhere to protocol specified radiation therapy guidelines was associated with decreased survival in RTOG 9704--a phaseⅢ trial of adjuvant chemotherapy and chemoradiotherapy for patients with resected adenocarcinoma of the pancreas[J]. Int J Radiat Oncol Biol Phys, 2012, 82(2):809-816. |
| [15] | 中华医学会外科学分会胰腺外科学组. 中国胰腺癌诊治指南(2021)[J]. 中华外科杂志, 2021, 59(7):561-577. |
| [16] | Palta M, Godfrey D, Goodman KA, et al. Radiation therapy for pancreatic cancer: executive summary of an ASTRO Clinical Practice Guideline[J]. Pract Radiat On-col, 2019, 9(5):322-332. |
| [17] | Khorana AA, Mangu PB, Berlin J, et al. Potentially cu-rable pancreatic cancer: American Society of Clinical Oncology Clinical Practice Guideline[J]. J Clin Oncol, 2016, 34(21):2541-2556. |
| [18] | Tempero MA, Malafa MP, Al-Hawary M, et al. Pancreatic adenocarcinoma, version 2.2021, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2021, 19(4):439-457. |
| [19] | Cohen SJ, Dobelbower RJ, Lipsitz S, et al. A randomized phaseⅢ study of radiotherapy alone or with 5-fluorouracil and mitomycin-C in patients with locally advanced adenocarcinoma of the pancreas: Eastern Co-operative Oncology Group study E8282[J]. Int J Radiat On-col Biol Phys, 2005, 62(5):1345-1350. |
| [20] | The Gastrointestinal Tumor Study Group. A multi-institutional comparative trial of radiation therapy alone and in combination with 5-fluorouracil for locally unresectable pancreatic carcinoma[J]. Ann Surg, 1979, 189(2):205-208. |
| [21] | Sultana A, Tudur SC, Cunningham D, et al. Systematic review, including meta-analyses, on the management of locally advanced pancreatic cancer using radiation/combined modality therapy[J]. Br J Cancer, 2007, 96(8):1183-1190. |
| [22] | Huguet F, Girard N, Guerche CS, et al. Chemoradiothe-rapy in the management of locally advanced pancreatic carcinoma: a qualitative systematic review[J]. J Clin Oncol, 2009, 27(13):2269-2277. |
| [23] | Wu L, Zhou Y, Fan Y, et al. Consolidative chemoradiotherapy after induced chemotherapy is an optimal regimen for locally advanced pancreatic cancer[J]. Front Oncol, 2019, 9:1543. |
| [24] | Schneider BJ, Ben-Josef E, McGinn CJ, et al. Capecitabine and radiation therapy preceded and followed by combination chemotherapy in advanced pancreatic cancer[J]. Int J Radiat Oncol Biol Phys, 2005, 63(5):1325-1330. |
| [25] | Lawrence TS, Eisbruch A, Shewach DS. Gemcitabine-mediated radiosensitization[J]. Semin Oncol, 1997, 24(2 Suppl 7):S7-S24. |
| [26] | Blackstock AW, Tepper JE, Niedwiecki D, et al. Cancer and leukemia group B (CALGB) 89805: phase Ⅱ chemoradiation trial using gemcitabine in patients with locoregional adenocarcinoma of the pancreas[J]. Int J Gastrointest Cancer, 2003, 34(2-3):107-116. |
| [27] | Cardenes HR, Moore AM, Johnson CS, et al. A phase Ⅱ study of gemcitabine in combination with radiation therapy in patients with localized, unresectable, pancreatic cancer: a Hoosier Oncology Group study[J]. Am J Clin Oncol, 2011, 34(5):460-465. |
| [28] | Li CP, Chao Y, Chi KH, et al. Concurrent chemoradiotherapy treatment of locally advanced pancreatic cancer: gemcitabine versus 5-fluorouracil, a randomized controlled study[J]. Int J Radiat Oncol Biol Phys, 2003, 57(1):98-104. |
| [29] | Brasiuniene B, Juozaityte E. The effect of combined treatment methods on survival and toxicity in patients with pancreatic cancer[J]. Medicina (Kaunas), 2007, 43(9):716-725. |
| [30] | Hurt CN, Falk S, Crosby T, et al. Long-term results and recurrence patterns from SCALOP: a phaseⅡ randomised trial of gemcitabine- or capecitabine-based chemoradiation for locally advanced pancreatic cancer[J]. Br J Cancer, 2017, 116(10):1264-1270. |
| [31] | Mahadevan A, Miksad R, Goldstein M, et al. Induction gemcitabine and stereotactic body radiotherapy for locally advanced nonmetastatic pancreas cancer[J]. Int J Radiat Oncol Biol Phys, 2011, 81(4):e615-e622. |
| [32] | Huguet F, Andre T, Hammel P, et al. Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase Ⅱ and Ⅲ studies[J]. J Clin Oncol, 2007, 25(3):326-331. |
| [33] | Hammel P, Huguet F, van Laethem JL, et al. Effect of chemoradiotherapy vs. chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib: the LAP07 randomized clinical trial[J]. JAMA, 2016, 315(17):1844-1853. |
| [34] | Perri G, Prakash L, Qiao W, et al. Response and survival associated with first-line FOLFIRINOX vs. gemcitabine and nab-paclitaxel chemotherapy for localized pancreatic ductal adenocarcinoma[J]. JAMA Surg, 2020, 155(9):832-839. |
| [35] | Gemenetzis G, Groot VP, Blair AB, et al. Survival in locally advanced pancreatic cancer after neoadjuvant the-rapy and surgical resection[J]. Ann Surg, 2019, 270(2):340-347. |
| [36] | Hayashi T, Nakamura T, Kimura Y, et al. Phase 2 study of neoadjuvant treatment of sequential S-1-based concurrent chemoradiation therapy followed by systemic chemotherapy with gemcitabine for borderline resectable pancreatic adenocarcinoma(HOPS-BR 01)[J]. Int J Radiat Oncol Biol Phys, 2019, 105(3):606-617. |
| [37] | Li Y, Feng Q, Jin J, et al. Experts′ consensus on intra-operative radiotherapy for pancreatic cancer[J]. Cancer Lett, 2019, 449:1-7. |
/
| 〈 |
|
〉 |
